Mastectomy reconstruction implants market seen reaching $3.58 billion by 2030

The Business Research Company projects the mastectomy reconstruction implants market will grow from $1.97 billion in 2025 to $3.58 billion by 2030, driven by rising breast cancer cases, broader reconstruction awareness and new implant techniques. North America held the largest market share in 2025, while outpatient settings and customizable implants are expected to gain ground.

Why it matters: - Demand for mastectomy reconstruction implants tracks breast cancer treatment and recovery needs, making the market a barometer for how reconstruction options are changing after surgery. - The forecast points to continued growth in implant-based reconstruction, with more patients likely to seek procedures that improve appearance and recovery outcomes. - The market outlook also signals a shift toward outpatient care and more customized implant options.

What happened: - The Business Research Company said the mastectomy reconstruction implants market will grow from $1.97 billion in 2025 to $2.23 billion in 2026. - The company projects the market will reach $3.58 billion by 2030. - The forecast implies a 12.9% CAGR from 2025 to 2026 and a 12.6% CAGR through 2030. - The report was published Aug. 14, 2026, from London. - More information is available through a free sample report.

The details: - Mastectomy reconstruction implants are medical devices used to restore breast size and shape after mastectomy. - The implants are typically made from silicone gel or saline. - Reconstruction can be done in two stages with a tissue expander first, or with a direct-to-implant procedure immediately after mastectomy. - Growth over the past year has been supported by rising breast cancer incidence, greater awareness of cosmetic reconstruction options and broader use of silicone and saline implants. - The report cites innovations in implant materials and customization as key future supports for growth. - It also points to more outpatient and ambulatory surgery center use, combined tissue expander and direct-to-implant methods, and more anatomical or teardrop-shaped implants. - The report says patient outcomes and minimally invasive techniques are becoming a stronger focus. - The market is also expected to see more two-stage and direct-to-implant procedures, wider adoption of customizable anatomical implants and greater attention to recovery and satisfaction. - North America held the largest share of the market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report update includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, key technologies and future trends, and updated graphics and tables.

Between the lines: - The market forecast suggests reconstruction is moving from a specialized post-cancer procedure toward a more standardized and technology-driven surgical category. - The emphasis on outpatient settings and minimally invasive techniques points to pressure for faster recovery, lower complexity and more convenience for patients and providers. - Rising breast cancer incidence remains the clearest demand driver, while customization appears to be the main differentiator in future product development.

What's next: - Growth will likely depend on how quickly implant makers and surgical centers adopt newer materials, direct-to-implant workflows and customization tools. - More market share could shift toward ambulatory surgery centers if outpatient reconstruction continues to expand. - Regional competition will likely remain centered in North America, with other regions evaluated for expansion opportunities in the report.